Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

XERO LIMITED Capital/Financing Update 2016

Dec 8, 2016

66106_rns_2016-12-08_fc9cdb50-b536-44cf-a6ef-5ab8f8f53030.pdf

Capital/Financing Update

Open in viewer

Opens in your device viewer

Rule 2.7, 3.10.3, 3.10.4, 3.10.5

Appendix 3B

New issue announcement, application for quotation of additional securities and agreement

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX’s property and may be made public.

Introduced 01/07/96 Origin: Appendix 5 Amended 01/07/98, 01/09/99, 01/07/00, 30/09/01, 11/03/02, 01/01/03, 24/10/05, 01/08/12, 04/03/13

Name of entity

Xero Limited

ABN

160 661 183 (ARBN)

We (the entity) give ASX the following information.

Part 1 -­ All issues

You must complete the relevant sections (attach sheets if there is not enough space).

1
+Class of+securities issued or
to be issued


(a) Ordinary Shares

(b) Options to subscribe for Ordinary
Shares in Xero Limited (Options)

(c)
Conditional
agreement
to
issue
Ordinary
Shares
in
Xero
Limited
(Restricted Stock UnitsorRSUs)

2
Number of+securities issued or
to be issued (if known) or
maximum number which may
be issued
(a) 1,008 Ordinary Shares

(b) 120,000 Options

(c)19,401 RSUs relating to the future issue of
up to 19,401 Ordinary Shares
(Restricted Stock UnitsorRSUs)


2
Number of+securities issued or
to be issued (if known) or

(a) 1,008 Ordinary Shares
maximum number which may
be issued

(b) 120,000 Options


(c)19,401 RSUs relating to the future issue of
up to 19,401 Ordinary Shares

3
Principal
terms
of
the
+securities
(e.g.
if
options,
exercise price and expiry date;
if partly paid+securities, the
amount outstanding and due
dates
for
payment;
if
+convertible
securities,
the
conversion price and dates for
conversion)

(a) Ordinary Shares issued upon exercise
of vested share options under the Xero
Limited (USA) Equity Incentive Scheme
(US Scheme); the exercise price for the
options was NZ$7.70 per option

(b) Grant of 120,000 Options under the
Xero Limited Restricted Stock Unit and
Option Plan (NZ) (NZ Plan) and US
Scheme as remuneration and incentive for
certain key employees based in New
Zealand
and
the
United
States,
respectively. The Options will vest (and
therefore become available for exercise) in
set percentages over a period of four
years, subject to the continued employment
of the respective key employee with the
Xero Limited Group on each vesting date.
The Options have a final exercise date of
five years from the grant date

(c) 19,401 RSUs have been granted
pursuant to the US Scheme as part of the
remuneration package of a certain key
employee based in the United States. The
number of RSUs granted was calculated
based on the total dollar entitlement of the
key employee divided by NZ$17.89, being
the 20 day volume weighted average
market price of Xero Limited’s Ordinary
Shares on the NZX Main Board through to
8 December 2016. The RSUs will vest (i.e.,
meaning an equivalent number of Ordinary
Shares in Xero Limited will be issued)
(Vest) on 31 March 2018, subject to the
terms
of
the
US
Scheme
and
the
employment
agreement
of
the
key
employee
  • See chapter 19 for defined terms.

Appendix 3B Page 2

  • 4 Do the[+] securities rank equally (a) Yes in all respects from the[+] issue date with an existing[+] class of (b) N/A quoted[+] securities? (c) N/A

  • If the additional[+] securities do not rank equally, please state: • the date from which they do

  • • the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment

  • • the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment

  • 5 Issue price or consideration

(a) 1,008 Ordinary Shares issued upon exercise of options;; the exercise price for the options was NZ$7.70 per option (b) N/A. Grant of 120,000 Options pursuant to the NZ Plan and US Scheme, as remuneration for certain key employees based in New Zealand and the United States, respectively. The exercise price is NZ$17.89 per Option (being the 20 day volume weighted average market price of an Ordinary Share in Xero Limited on the NZX Main Board through to 8 December 2016) (c) 19,401 RSUs were granted at a value of NZ$17.89 each, being the 20 day volume weighted average market price of Xero Limited’s Ordinary Shares on the NZX Main Board through to 8 December 2016. No cash consideration is required to be paid for these RSUs to Vest


Purpose of the issue
(If issued as consideration for
the acquisition of assets, clearly
identify those assets)








6a
Is the entity an+eligible entity
that
has
obtained
security
holder
approval
under
rule
7.1A?

If Yes, complete sections 6b –
6h in relation to the+securities
the subject of this Appendix 3B,
and comply with section 6i


6b
The date the security holder
resolution under rule 7.1A was
passed


6c
Number of+securities issued
without security holder approval
under rule 7.1


6d
Number of+securities issued
with security holder approval
under rule 7.1A


6e
Number of+securities issued
with security holder approval
under rule 7.3, or another
specific
security
holder
approval
(specify
date
of
meeting)



6f
Number of+securities issued
under an exception in rule 7.2
(a) Issue of Ordinary Shares upon exercise
of vested options under the US Scheme as
part of the remuneration package of an
employee based in the United States

(b) Grant of 120,000 Options under the NZ
Plan and US Scheme as remuneration and
incentive for certain key employees

(c) Grant of 19,401 RSUs pursuant to the
US Scheme as part of the remuneration
package of a certain key employee based
in the United States
N/A
N/A
N/A
N/A
N/A
N/A
  • See chapter 19 for defined terms.

Appendix 3B Page 4

6g
If+securities issued under rule
7.1A, was issue price at least
75% of 15 day VWAP as
calculated under rule 7.1A.3?
Include the+issue date and
both values. Include the source
of the VWAP calculation.


6h
If+securities were issued under
rule
7.1A
for
non-cash
consideration, state date on
which valuation of consideration
was released to ASX Market
Announcements


6i
Calculate the entity’s remaining
issue capacity under rule 7.1
and rule 7.1A – complete
Annexure 1 and release to ASX
Market Announcements


7
+Issue dates
Note: The issue date may be prescribed by
ASX (refer to the definition of issue date in
rule 19.12). For example, the issue date for
a pro rata entitlement issue must comply with
the applicable timetable in Appendix 7A.
Cross reference: item 33 of Appendix 3B.




8
Number
and
+class
of
all
+securities
quoted
on
ASX
(including the
+securities in
section 2 if applicable)





9
Number
and
+class
of
all
+securities not quoted on ASX
(including the
+securities in
section 2 if applicable)


N/A N/A N/A
Number +Class
(a) 137,545,165 Ordinary
Number +Class
(b) 2,505,557


Options (convertible
into Ordinary Shares
on a 1:1 basis), taking
into account all
forfeited options to
date and the exercise
of 1,008 options and
the grant of 120,000
Options in
accordance with the
terms of this
Appendix 3B

==> picture [230 x 229] intentionally omitted <==

----- Start of picture text -----

(c) 677,899 Restricted Stock
Units or RSUs (a
conditional
contractual right to be
issued up to 677,899
Ordinary Shares),
taking into account all
forfeited RSUs to
date and the grant of
19,401 RSUs as set
out in this Appendix
3B
----- End of picture text -----

10 Dividend policy (in the case of a (a) As for all Ordinary Shares trust, distribution policy) on the increased capital (interests) (b) N/A (c) N/A

Part 2 -­ Pro rata issue

11 Is security holder approval N/A required? 12 Is the issue renounceable or N/A non-­renounceable? 13 Ratio in which the[+] securities will N/A be offered 14 +Class of +securities to which N/A the offer relates 15 +Record date to determine N/A entitlements 16 Will holdings on different N/A registers (or subregisters) be aggregated for calculating entitlements?

  • See chapter 19 for defined terms.

Appendix 3B Page 6

17
Policy for deciding entitlements
in relation to fractions



18
Names of countries in which the
entity has security holders who
will not be sent new offer
documents
Note: Security holders must be told how their
entitlements are to be dealt with.
Cross reference: rule 7.7.


19
Closing date for receipt of
acceptances or renunciations


20
Names of any underwriters




21
Amount of any underwriting fee
or commission


22
Names of any brokers to the
issue




23
Fee or commission payable to
the broker to the issue


24
Amount of any handling fee
payable to brokers who lodge
acceptances or renunciations on
behalf of security holders


25
If the issue is contingent on
security holders’ approval, the
date of the meeting


26
Date
entitlement
and
acceptance
form
and
offer
documents
will
be
sent
to
persons entitled


27
If the entity has issued options,
and the terms entitle option
holders
to
participate
on
exercise, the date on which
notices will be sent to option
holders


28
Date rights trading will begin (if
applicable)
N/A
N/A
N/A

N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
29
Date rights trading will end (if
applicable)




30
How do security holders sell
their entitlements in full through
a broker?


31
How do security holders sell part
of their entitlements through a
broker
and
accept
for
the
balance?


32
How do security holders dispose
of their entitlements (except by
sale through a broker)?


33
+Issue date

N/A
N/A
N/A
N/A
N/A

Part 3 -­ Quotation of securities

You need only complete this section if you are applying for quotation of securities

34 Type of[+] securities (tick one)

  • (a) (in respect of the “Ordinary Shares” described in Part 1 only) +Securities described in Part 1

  • (b)[All other ][+][securities ]

Example: restricted securities at the end of the escrowed period, partly paid securities that become fully paid, employee incentive share securities when restriction ends, securities issued on expiry or conversion of convertible securities

Entities that have ticked box 34(a)

Additional securities forming a new class of securities

Tick to indicate you are providing the information or documents

  • 35[If the ] the additional[+][securities are ][+] securities, and the number and percentage of additional[+][equity securities, the names of the 20 largest holders of ] +securities held by those holders

  • 36 +[If the ] securities setting out the number of holders in the categories[+][securities are ][+][equity securities, a distribution schedule of the additional ]

  • See chapter 19 for defined terms.

Appendix 3B Page 8

1 -­ 1,000 1,001 -­ 5,000 5,001 -­ 10,000 10,001 -­ 100,000 100,001 and over 37[A copy of any trust deed for the additional ][+][securities ]

Entities that have ticked box 34(b)

==> picture [407 x 456] intentionally omitted <==

----- Start of picture text -----

38 Number of [+] securities for which
+quotation is sought
39 +Class of +securities for which
quotation is sought
40 Do the [+] securities rank equally in
all respects from the [+] issue date
with an existing [+] class of quoted
+securities?
If the additional [+] securities do not
rank equally, please state:

the date from which they do

the extent to which they
participate for the next
dividend, (in the case of a
trust, distribution) or interest
payment

the extent to which they do
not rank equally, other than in
relation to the next dividend,
distribution or interest
payment
41 Reason for request for quotation
now
Example: In the case of restricted securities,
end of restriction period
(if issued upon conversion of
another [+] security, clearly identify
that other [+] security)
Number +Class
----- End of picture text -----

42 Number and +class of all +securities quoted on ASX (including the +securities in clause 38)

  • See chapter 19 for defined terms.

Appendix 3B Page 10

Quotation agreement

  • 1 +Quotation of our additional +securities is in ASX’s absolute discretion. ASX may quote the[+] securities on any conditions it decides.

  • 2 We warrant the following to ASX.

  • The issue of the[+] securities to be quoted complies with the law and is not for an illegal purpose.

  • There is no reason why those[+] securities should not be granted +quotation.

  • An offer of the[+] securities for sale within 12 months after their issue will not require disclosure under section 707(3) or section 1012C(6) of the Corporations Act.

Note: An entity may need to obtain appropriate warranties from subscribers for the securities in order to be able to give this warranty

  • Section 724 or section 1016E of the Corporations Act does not apply to any applications received by us in relation to any[+] securities to be quoted and that no-­one has any right to return any[+] securities to be quoted under sections 737, 738 or 1016F of the Corporations Act at the time that we request that the[+] securities be quoted.

  • If we are a trust, we warrant that no person has the right to return the +securities to be quoted under section 1019B of the Corporations Act at the time that we request that the[+] securities be quoted.

  • 3 We will indemnify ASX to the fullest extent permitted by law in respect of any claim, action or expense arising from or connected with any breach of the warranties in this agreement.

  • 4 We give ASX the information and documents required by this form. If any information or document is not available now, we will give it to ASX before +quotation of the +securities begins. We acknowledge that ASX is relying on the information and documents. We warrant that they are (will be) true and complete.

Sign here: ............................................................ Date: 9 December 2016 ( ~~Director/~~ Company secretary) Print name: Chaman Sidhu

  • See chapter 19 for defined terms.

Appendix 3B Page 11

XX/01/2015

Appendix 3B – Annexure 1

Calculation of placement capacity under rule 7.1 and rule 7.1A for eligible entities

Introduced 01/08/12 Amended 04/03/13

Part 1

==> picture [415 x 463] intentionally omitted <==

----- Start of picture text -----

Rule 7.1 – Issues exceeding 15% of capital
Step 1: Calculate “A”, the base figure from which the placement
capacity is calculated
Insert number of fully paid [+] ordinary
securities on issue 12 months before the
+issue date or date of agreement to issue
Add the following:
• Number of fully paid [+] ordinary securities
issued in that 12 month period under an
exception in rule 7.2
• Number of fully paid [+] ordinary securities
issued in that 12 month period with
shareholder approval
• Number of partly paid [+] ordinary
securities that became fully paid in that
12 month period
Note:
• Include only ordinary securities here –
other classes of equity securities cannot
be added
• Include here (if applicable) the securities
the subject of the Appendix 3B to which
this form is annexed
• It may be useful to set out issues of
securities on different dates as separate
line items
Subtract the number of fully paid [+] ordinary
securities cancelled during that 12 month
period
“A”
----- End of picture text -----

  • See chapter 19 for defined terms.

Appendix 3B Page 12

Step 2: Calculate 15% of “A”
“B” 0.15
[Note: this value cannot be changed]
Multiply“A” by 0.15
Step 3: Calculate “C”, the amount of placement capacity under rule 7.1
that has already been used
Insertnumber of+equity securities issued
or agreed to be issued in that 12 month
period not counting those issued:

Under an exception in rule 7.2

Under rule 7.1A

With security holder approval under rule
7.1 or rule 7.4
Note:

This applies to equity securities, unless
specifically excluded – not just ordinary
securities

Include here (if applicable) the securities
the subject of the Appendix 3B to which
this form is annexed

It may be useful to set out issues of
securities on different dates as separate
line items
“C”
Step 4: Subtract “C” from [“A” x “B”] to calculate remaining
placement capacity under rule 7.1
“A” x 0.15
Note: number must be same as shown in
Step 2
Subtract“C”
Note: number must be same as shown in
Step 3
Total[“A” x 0.15] – “C”
[Note: this is the remaining placement
capacity under rule 7.1]
  • See chapter 19 for defined terms.

Appendix 3B Page 13

XX/01/2015

Part 2

Rule 7.1A – Additional placement capacity for eligible entities

Step 1: Calculate “A”, the base figure from which the placement capacity is calculated

“A” Note: number must be same as shown in Step 1 of Part 1

Step 2: Calculate 10% of “A”

“D” 0.10 Note: this value cannot be changed Multiply “A” by 0.10

Step 3: Calculate “E”, the amount of placement capacity under rule 7.1A that has already been used

Insert number of[+] equity securities issued or agreed to be issued in that 12 month period under rule 7.1A

  • Notes: • This applies to equity securities – not just ordinary securities

  • • Include here – if applicable – the securities the subject of the Appendix 3B to which this form is annexed

  • • Do not include equity securities issued under rule 7.1 (they must be dealt with in Part 1), or for which specific security holder approval has been obtained

  • • It may be useful to set out issues of securities on different dates as separate line items

  • “E”

  • See chapter 19 for defined terms.

Appendix 3B Page 14

Step 4: Subtract “E” from [“A” x “D”] to calculate remaining
placement capacity under rule 7.1A
“A” x 0.10
Note: number must be same as shown in
Step 2
Subtract“E”
Note: number must be same as shown in
Step 3
Total[“A” x 0.10] – “E”
Note: this is the remaining placement
capacity under rule 7.1A


  • See chapter 19 for defined terms.

Appendix 3B Page 15

XX/01/2015